Cross Cancer Institute

Pacylex Pharmaceuticals Announces the Initiation of a Phase 1 Clinical of PCLX-001, a First-In-Class NMT Inhibitor, in Non-Hodgkin's Lymphomas and Solid Tumor Patients

Tuesday, September 14, 2021 - 9:13pm

Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .

Key Points: 
  • Edmonton, Alberta--(Newsfile Corp. - September 14, 2021) - To view the full announcement, including downloadable images, bios, and more, click here .
  • PCLX-001 is the first clinical candidate sponsored by Pacylex Pharmaceuticals to reach the clinical stage.
  • Upcoming enrollment of 20-30 patients to begin at the Cross Cancer Institute in Edmonton and expand to Princess Margaret Hospital in Toronto and the BC Cancer Agency in Vancouver.
  • This open label, dose escalation study will examine the safety and tolerability of PCLX-001.